1. Home
  2. ACCL vs PRLD Comparison

ACCL vs PRLD Comparison

Compare ACCL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACCL

Acco Group Holdings Limited Ordinary Shares

N/A

Current Price

$3.10

Market Cap

57.8M

ML Signal

N/A

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

HOLD

Current Price

$2.59

Market Cap

69.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACCL
PRLD
Founded
2009
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Professional Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.8M
69.1M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
ACCL
PRLD
Price
$3.10
$2.59
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
82.0K
499.8K
Earning Date
02-20-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
2.91
N/A
EPS
0.08
N/A
Revenue
$4,888,824.00
$10,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$35.11
N/A
Revenue Growth
11.91
250.00
52 Week Low
$2.10
$0.61
52 Week High
$5.00
$4.22

Technical Indicators

Market Signals
Indicator
ACCL
PRLD
Relative Strength Index (RSI) N/A 60.23
Support Level N/A $2.37
Resistance Level N/A $3.00
Average True Range (ATR) 0.00 0.28
MACD 0.00 0.03
Stochastic Oscillator 0.00 63.64

Price Performance

Historical Comparison
ACCL
PRLD

About ACCL Acco Group Holdings Limited Ordinary Shares

Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: